IsoRay, Inc. (NASDAQ: ISR)
IsoRay, has had an interesting week in the market thus far. After announcing that Cesium-131 was indeed effective in the treatment of cancer, the company went under attack by Adam Feuerstein; who discredited their press release and drove the stock price down. However, I’ve said a few times since then that I still have faith in IsoRay and that Adam Feuerstein missed a few key points in his peer review of the company. Now the only question is, “When will we start seeing gains again? Today, we’ll talk about the results of Cesium-131 and what Adama Feuerstein seems to have left out of his review. Also, we’ll talk about what I think we’re going to see from ISR moving forward both in the short and long run. So, let’s get right to it.
Positive Cesium-131 Data From ISR
Last week, IsoRay published a press release that announced the effectiveness of Cesium-131 in non-small cell lung cancer; and the data was overwhelmingly positive. Localization was successful in 96% of the patients while the 5 year survival rate was at 100%; proving that Cesium-131 is indeed effective in treating the ailment.
Adam Feuerstein Attacks IsoRay
The day after the ISR press release Adam Feuerstein published a peer review of the company and Cesium-131; essentially downplaying the positive news. In his peer review, Feuerstein explained that Cesium-131 is effective, but no more effective than the standard care that cancer patients receive at the moment. However, he missed a big point…
The Current Care Is Dreadful!
The major fact that Feuerstein seems to have left out of his peer review is that the care he is comparing to IsoRay’s Cesium-131 is a month’s long treatment including the use of chemo therapy and radiation. Not only does this treatment have extremely severe side effects, it also threatens the patient’s friends, family members, and caregivers. That’s because the radioactive isotopes used in current treatments have a half-life of 6 to 9 months. So, cancer patients under treatment are essentially radioactive; which could lead to harm for those who spend time with the patient.
Cesium-131 Combats The Major Issues Associated With Current Care
With Cesium-131, the three major issues associated with the current care plan for non-small cell lung cancer patient are all solved problems when we look at Cesium-131…
- Length Of Treatment – Instead of a month’s long treatment plan, Cesium-131 is only administered once.
- Side Effects – While Cesium-131 does have side effects, there are nowhere near as horrid as those we see in the chemo/radiation mix.
- Family, Friends, and Caregivers – Finally, the radioactive isotope in Cesium-131 only has a days long half-life; meaning that friends, family, and caregivers that spend time with the patient are not in danger.
So, while Feuerstein was right about the fact that Cesium-131 is as effective as current treatments, not more effective, he was wrong in leaving out the primary reasons that Cesium-131 is likely to succeed.
When Will ISR Start To Climb Again?
This is the million dollar question my friends; and I have to admit, I have no crystal ball, nor can I tell the future. With that said, I can’t give you a date or even a date range. However, I can say that I do expect the stock to start popping back up sooner rather than later.
What Do You Think?
When do you think ISR will start to climb again? Let us know your opinion in the comments below!